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Summary.  
Background: It has been observed that migraineurs show a higher risk of thrombosis and that the most frequent 
symptom reported by patients with antiphospholipid syndrome is headache, especially migraine. Objectives: The aim 
of our research was to evaluate the prevalence of antiphospholipid antibodies (aPL) in a random cohort of 
migraineurs. Patients/Methods: This analytic, comparative case study was performed to evaluate the prevalence of 
antiphospholipid antibodies by comparing a population of migraineurs with and without aura with sex- and age-
matched controls. Both the diagnosis of migraine and the laboratory diagnosis of aPL positivity were made on the 
basis of the most recent international guidelines. Results: Between September 2008 and August 2009, we recruited 
284 consecutive patients (225 women and 59 men, 203 without aura and 81 with aura) and 225 controls (174 women 
and 51 men). Positivity for at least one test for aPL (LAC, ACA IgG or antiß2GLP1 IgG) was detected and confirmed in 
12% (n = 33) of patients and in 3% (n = 7) of controls (odds ratio, 4.08; confidence interval, 1.77–9:39; P = 0.0004). 
Two of the patients had triple positivity for aPL (LAC, ACA and antiß2GLP1) and one had double positivity (LAC and 
antiß2GLP1); none of the controls showed multiple positivity. Conclusions: Our data show that migraineurs have a 
significantly higher prevalence of antiphospholipid antibodies, and point towards the fact that the two conditions may 
be comorbid or even that migraine may be an early sign for identifying patients with aPL positivity. 
 
Introduction  
Migraine is the most frequent type of primary headache, and is characterized by severe, predominantly unilateral 
throbbing pain associated with phonophobia, photophobia, nausea and vomiting [1]. Various diseases are believed to 
be comorbid with migraine, and in recent years particular attention has been paid to the vascular complications of 
migraine. Furthermore, a significantly increased risk of stroke and cerebrovascular lesions has also been documented 
[2–4]. In the 1980s, Hughes and colleagues first described the antiphospholipid syndrome (APS) [5], and headache 
andmigraine are currentlyincluded among the symptoms [6]. There are several studies that have looked for a 
correlation between migraine and antiphospholipid antibodies (aPL), but so far data on the prevalence of 
antiphospholipid antibodies and any possible relationship with migraine are conflicting and incomplete, with a 
prevalence ranging from 0% to 30% of patients[7–19].Recent data drawn from theEuropean Registry for APS revealed 
that the most frequent symptom in APS is headache, mostly classified as migraine with and without aura [20,21]. 
More recent data taken from the Euro-Phospholipid Project confirmed a 20% prevalence of migraine in patients with 
APS [22]. It was therefore hypothesized that APS may be the link between migraine and stroke, and recommendations 
weremade to search for aPLin patients suffering frommigraines or from recurrent headaches [23]. None of the existing 
studies based on current guidelines for the diagnosis of migraine or for the laboratory diagnosis of APL is large enough 
to evaluate the possible correlation between migraine and aPL. This is even more important because headache is not 
presently among the diagnostic criteria for APS. We therefore designed this singlecenter, laboratory blinded, analytic 
comparative case study to assess the prevalence of aPL in patients with migraine. 
 
Patients and methods  
Patients  
Patients were enrolled between 1 September 2008 and 31 August 2009. We compared two groups: the first group 
included patients with migraine who were consecutively visited at our Headache Center, and who routinely 
underwent blood chemistry examinations for comorbidity. The second was a control group made up of volunteers 
who did not suffer from headache, and included employees of our hospital who volunteered to participate in the 
study while undergoing their routine annual blood test for occupational medicine. The inclusion criterion for patients 
was migraine, as diagnosed according to the International Classification of Headache Disorders criteria [1]; exclusion 
criteria included the presence of other types of headache and the use of anticoagulation therapy. Exclusion criteria for 
controls were the presence of headache and/or the use of anticoagulants. Patients and controls were sex and age 
matched (±5 years). The severity of headache was estimated using an index of severity (defined as the sum of the 
severity of each day of headache per month). Severity was defined as: 1 = mild pain that does not need therapy and is 
not disabling; 2 = moderate intensity of pain, disabling, requiring therapy, well manageable with treatment; 3 = very 
severe pain, severely disabling, requiring therapy, poorly responsive to symptomatic drugs). The patients were all seen 
by a neurologist who is experienced in headache diagnosis, and a computer-assisted history was drawn up. The 
same information on medical history was collected from the control subjects by means of a questionnaire. 
 
Laboratory methods 
All patients and controls were evaluated for blood cell count, partial thromboplastin time (PTT), prothrombin time 
(PT), lupus anticoagulant (LAC), anticardiolipin antibodies (ACA), and antibodies to beta 2 glycoprotein (Ab2G). The 
laboratory methods we used included the coagulation method (Roche Diagnostics, Stago, France), Stage Rack: LA-PTT 
lupus anticoagulant, confirm test, ratio of basal and mix with pool of sera LAC SCT, SCT confirm test, SCT normalized 
ratio, LAC Russell Viper Venom (DRVVT) and DRVVT confirm ratio) for LAC. We used microtiter IEMA (Aesku 
Diagnostics, Wendelsheim, Germany); AESKULISA Cardiolipin IgG and IgM) for ACA, and microtiter IEMA (Aesku 
Diagnostics; AESKULISA ß2 Glycoprotein IgG and IgM) for Ab2G. 
 
Sampling procedure  
Sampling was carried out with minimal stasis, using the Vacutainer system. We used 4.5 mL tubes containing sodium 
citrate 0.109 mol L)1 (3.2%) as the anticoagulant for LAC. Plasma was separated from the corpuscular phase within 3 h 
of collection by double centrifugation at 1800 g (15 min for each spin). The lack of platelets in plasma was confirmed 
by counting performed with the Sysmex SE 2100 system, and the search for the LAC was performed every day within 5 
h of collection using STA-R Roche equipment. Test tubes without anticoagulant and with gel separator were used for 
the detection of ACA and Ab2G on blood that was drawn at the same time as samples for LAC testing, using the 
Vacutainer system. The test tubes were centrifuged within 2 h of collection (time varying between 30 min and 2 h) and 
the serum was kept in the original tube with the plug in place, in the refrigerator at 4–8 C, and examined within 7 days 
of collection. Tests were performed by the Triturus analyzer, made by GRIFOLS (Parets del Valle´s, Barcelona, Spain). 
 
Positivity criteria  
Patients having at least two confirmed positive test results at intervals of > 12 weeks were considered positive. The 
tests were considered positive if LAC positivity of any strength was observed with at least two out of three (PTT-LA, 
SCT, DRVVT) positive tests (low positivity = ratio 1.20–1.50, moderate positivity = ratio 1.50–1.80, high positivity = 
ratio > 1.80); ACA IgG or Ab2G IgG were considered positive if IgG was > 40 (moderate positivity = IgG 40–80, high 
positivity = IgG > 80). With regard to positivity criteria, we followed both the international criteria for the diagnosis of 
APS [6], as well as the latest recommendations stating that only medium-high titers of IgG, Ab2G or ACA should be 
considered positive [24]. Our hospital laboratory regularly undergoes regional quality controls carried out by the 
Regional Consortium for APS. 
 
Sample size We estimated a likely prevalence of aPL among controls of 1– 5%. We then calculated that in order to 
detect any significant differences between the two groups, using Delta 10%, 5% alpha error, beta error 90% and the 
two-tailed test, we would have to recruit between 136 and 206 subjects per cohort. 
 
Statistical analysis  
Analysis of variance for groups was performed using the SAS system for PCs. Data were adjusted for sex using the 
Cochran– Mantel–Haenszel statistics, and then stratified by sex. We used odds ratio (OR) (confidence interval [CI] 
95%) as a measure of statistical significance. The study was carried out in collaboration with the University of Turin, 
Masters course for rare diseases. All the necessary authorizations were obtained. Patients and controls provided 
informed consent allowing the use of personal, clinical and instrumental data. 
Results  
In 1 year, 284 patients (225 women and 59 men) and 225 controls (174 women and 51 men) were recruited. The 
mean age of the patients was 39 years, on average 5 years younger than the controls. Among migraineurs, 203 
suffered from migraine without aura (M) and 81 had migraine with aura (MA). Average age at onset of headache was 
18 years, while the frequency of the attacks was 9 days month)1 and the index of severity was 20. These data were 
similar in subgroups of migraineurs with and without aura. Table 1 shows the details. Positivity for aPL was confirmed 
in 12% of patients (n = 33) and in 3% (n = 7) of the controls (OR, 4.08; CI, 1.77–9.39; P = 0.0004). Table 2 shows the 
details. Positivity for LAC was confirmed in nine patients (six patients, ratio < 1.50; three patients, ratio > 1.80) but in 
none of the controls (OR, 8.52; CI, 1.07–67.41; P = 0.006). ACA positivity was similar in the two groups (four patients 
with moderate IgG titer and one control with high IgG titer). Regarding the positivity for Ab2G, it was significantly 
higher in migraineurs (OR 3.51 (CI 1.41–8.71) P = 0.004), both in the subgroup of migraine without aura (OR, 3.99; CI, 
1.33–11.93; P = 0.008) and the subgroup of migraine with aura (OR, 3.28; CI, 1.26– 8.52; P = 0.01) (11 patients with 
moderate IgG positivity, 14 patients with high IgG positivity, two controls with moderate positivity and four controls 
with high positivity). After stratification by sex, statistical significance still remained for women in general, and for 
migraine without aura. Two of the patients (one male and one female) were positive for LAC, ACA and Ab2G, and one 
patient (a female) was positive for LAC and Ab2G, while none of the controls had multiple positivity. Subgroup analysis 
on the basis of age at onset, frequency of monthly headache and headache severity index showed a significantly 
higher prevalence of aPL positivity in all categories, as well as a trend towards higher positivity among migraineurs 
suffering from greater frequency and more severe forms (see Table 3 for details). We also evaluated patients and 
control subjects for other possible diseases, and were able to rule out inflammatory connective tissue disorders. 
 
Discussion  
To our knowledge, ours is the first cohort study carried out on a large population of migraine patients who were 
studied using shared criteria, on the basis of current guidelines for both the neurological diagnosis of migraine [1] and 
the laboratory diagnosis for aPLs [5,24]. Comparing our data with those of previous studies is difficult because the 
populations and diagnostic and laboratory parameters are heterogeneous. The study by Avcin et al. [9] is the only one 
that investigated both ACA and Ab2G with welldefined laboratory criteria, sampling methods and parameters of 
antibody positivity, and that used the International Classi- fication to evaluate migraine. The authors studied a small 
population of children with migraine, using two control groups, one consisting of children with tension headache and 
the other of healthy children. These same authors repeated the laboratory tests over time and confirmed positivity at 
any titer for IgM or IgG ACA or Ab2G in about 16% of children in each group, but positive medium-titer was only 
confirmed in two migraine patients (5%) over time. Our study, which was conducted on an adult population, revealed 
a confirmed-overtime positivity at any titer in approximately 17% of patients compared with 4% of controls (data not 
shown). This percentage is similar to what was found in the population studied by Avcin et al. [9], whereas confirmed 
positivity in the medium-high titers was observed in 12% of our patients. All other published works only involved 
studies on ACA [8–19], while LAC was only mentioned in three older works that described the first case reports or 
selected neurological patients [7,8,19]. The tests for aPL were repeated over time in only three cases to confirm 
results [13,18,19] and included comparisons between patients and controls [10–13,15,17]. On average, few patients 
were studied in those works and the results that were obtained vary broadly (from 0% to 37%). No differences were 
detected between the various subtypes of migraine, nor was any relationship observed between aPL and migraine 
with aura [10,12,15,17–19]. Furthermore, among migraineurs, we found a 4% prevalence of APS syndrome (eight 
vascular APS and four obstetric APS), compared with 0.4% of controls (one case of vascular APS). Although the study 
of these data is not among the objectives of this study, they may suggest a possible correlation between migraine and 
aPL as well as one between migraine and APS. Whether there is a link between migraine and aPLs, and what that link 
might be is not clear. They may be genetically related, but both are heterogeneous and multifactorial diseases, and no 
specific causative gene has yet been identified [25–27]. They share the same male-female distribution [28–39], and 
furthermore, a possible common pathogenetic basis might be platelet activation and similar serotonergic involvement 
[31–36]. We must also take into consideration that complement activation is common in both migraine [37–39] and 
APS [40–42]. Migraine is not considered a clinical criterion for the diagnosis of antiphospholipid antibody syndrome, 
even in the presence of elevated levels of plasma aPLs. Such patients are defined as “confirmed asymptomatic aPL 
positive” as they do not have documented thrombotic vascular events. However, we believe that on the basis of our 
data and on those that are emerging from the European Registry [21,22], the current exclusion of migraine from 
among the diagnostic criteria should be reconsidered. 
 
Conclusion 
Our study is the first to demonstrate a higher prevalence of aPL positivity in migraineurs compared with controls by 
means of a large analytical comparative population study. This study involved appropriate selection of patients and 
controls, and strict application of criteria for laboratory research, for the definition of aPL positivity, and for the clinical 
definition of migraine. It is not clear what the link between migraine and aPL is. Our data point towards the fact that 
the two conditions may be comorbid. Further studies applying clinical and laboratory diagnostic criteria both for 
migraine and for the assessment of aPL are needed to confirm our data. Additional work is also required to assess 
whether any active therapy for hemostasis may be advantageous even for migraine prophylaxis. 
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